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demonstration that C1- IHCO, - exchange activity is 
present in intact hepatocytes and may be the principal 
mechanism responsible for recovery from intracellular 
alkaline challenge. These studies also provide a strong 
foundation for future investigation of related questions 
regarding the overall contribution of C1- IHCO, - ex- 
change to other cellular functions including biliary 
HCO, - secretion and bile formation. Unlike Na + /H + 
exchange and Na + MCO, - cotransport, C1- /HCO, - 
exchange is located in the canalicular membrane. These 
studies predict that intracellular alkalosis would be 
followed by rapid alkalinization of canalicular bile and 
that transport activity would be sensitive to C1- in the 
canalicular rather than the extracellular space. Reg- 
ulation by factors other than C1- and HC0,- con- 
centration that alter the “set point” or rate of 
transport including H +  ions and Ca2’ - or cyclic 
AMP-dependent signaling will also be of great interest. 
Finally, it will be important to determine how regu- 
lation of C1-MC0,- exchange is integrated with 
other mechanisms of H + and HCO, - transport. It is 
attractive to speculate that a balance exists between 
HCO, - influx through Na + /HCO, - cotransport and 
efflux through C1- MCO, - exchange. Because these 
transporters are located in separate membrane do- 
mains, coregulation might contribute to transcellular 
movement of HC0,- from the sinusoidal to the can- 
alicular space and the regulation of pHi. 
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PROVOCATIVE GENE THERAPY STRATEGY 
FOR THE TREATMENT OF 
HEPATOCELLULAR CARCINOMA 
Huber BE, Richards CA, Krenitsky TA. Retroviral- 
mediated gene therapy for the treatment of hepatocel- 
lular carcinoma: an innovative approach for cancer 
therapy. Proc Natl Acad Sci USA 1991;88:8039-8043. 
ABSTRACT 
An approach involving retroviral-mediated gene 
therapy for the treatment of neoplastic disease is 
described. This therapeutic approach is called “virus- 
directed enzymelprodrug therapy” (WEPT). The 
WEPT approach exploits the transcriptional differ- 
ences between normal and neoplastic cells to achieve 
selective killing of neoplastic cells. We now describe 
development of the WEPT approach for the treatment 
of hepatocellular carcinoma. Replication-defective, 
amphotrophic retroviruses were constructed con- 
taining a chimeric varicella-zoster virus thymidine 
kinase (VZV TK) gene that is transcriptionally regu- 
lated by either the hepatoma-associated wfetoprotein 
or liver-associated albumin transcriptional regulatory 
sequences. Subsequent to retroviral infection, ex- 
pression of VZV TK was limited to either a-fetoprotein- 
or albumin-positive cells, respectively. VZV TK 
metabolically activated the nontoxic prodrug 
6-methoxypurine arabinonucleoside (araM), ulti- 
mately leading to the formation of the cytotoxic anab- 
olite adenine arabinonucleoside triphosphate 
(araATP). Cells that selectively expressed VZV TK 
became selectively sensitive to araM due to the VZV 
TK-dependent anabolism of araM to araATP. Hence, 
these retroviral-delivered chimeric genes generated 
tissue-specik expression of VZV TK, tissue-specific 
anabolism of araM to araATp, and tissue-specific cyto- 
toxicity due to araM exposure. By utilizing such retro- 
viral vectors, araM was anabolized to araAW in hep 
atoma cells, producing a selective cytotoxic effect. 
COMMENTS 
The rapid advance in gene transfer technology has 
fueled speculation with regard to future human appli- 
cations. This article defines a gene therapy strategy for 
the treatment of HCC in patients and then thoroughly 
explores its feasibility in vitro. The strategy exploits two 
well-described phenomena, which are as follows: (a) the 
ability of tissue-specific regulatory elements to selec- 
tively drive gene expression in different types of cells and 
(b) the ability of the varicella-zoster virus thymidine 
kinase (TK) enzyme to metabolically activate the 
prodrug 6 methoxypurine arabinonucleoside (araM) to 
adenine arabinonucleoside triphosphate (ardTP).  The 
prodrug, araM, is not toxic, but araATP is toxic to the 
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cells in which it is synthesized. The TK gene was 
transferred into cultured hepatoma cells using a retro- 
viral expression vector, and the gene was expressed 
when it was driven by the AFP promoter. When exposed 
to araM, the transfected cells evidently produced 
araATP and died. 
This gene therapy strategy sets out to kill cancerous 
cells while allowing noncancerous cells to live. First, 
cancerous and noncancerous cells would be transduced 
with the TK gene driven by the a-fetoprotein (AFP) 
promoter. Next, the gene is ideally only turned on in the 
cancer cells. Tissue-specific promoters are used to 
selectively drive transgene expression in cancer cells as 
opposed to healthy ones. The strategy depends on 
transduced carcinomatous cells actively transcribing the 
TK gene when it is driven by the AFP regulatory unit, 
whereas nonmalignant hepatocytes would not turn on 
this gene. Finally, cells which turn on the TK gene 
activate the prodrug araM to araATP and die, whereas 
cells that do not express the TK enzyme should not 
activate the prodrug and therefore should survive. 
For this gene therapy strategy to cure cancer in uiuo, 
most or all tumor cells would be transduced with the TK 
retroviral expression vector driven by the AFP pro- 
moter. Tumor cells would activate transcription driven 
by the AFP regulatory unit, whereas healthy cells would 
not activate transcription. This assumes that all tumor 
cells possess the tissue specificity to activate tran- 
scription driven by the AFP regulatory unit. If a tumor 
contained cells with heterogeneous transcriptional pro- 
miscuity, clones of malignant cells that did not turn on 
genes driven by the AFP regulatory unit would be 
selected. Carcinomatous cells that did not activate 
transcription of the AFP promoter would not be ablated 
using this strategy. 
Given the current efficiency of retroviral expression 
vectors, this technique is not presently a feasible 
approach to cure cancer in uiuo. The investigators used 
retroviral expression vectors to transfer the TK gene 
into eukaryotic cells, a technique that is presently 
optimally effective at  transfering genes into approxi- 
mately 20% of hepatocytes in primary culture (1). The 
increased propensity of retroviruses to infect dividing 
cells (2) might favor the in uiuo transduction of tumor 
cells over quiescent hepatocytes. In uiuo gene trans- 
duction efficiency would probably still be low. Even 
under conditions of intense hepatocellular division after 
Dart ia l  hepatectomv. 5% of hepatocvtes were infected in r- 
uiuo (3) .  Naturally, a miraculous propensity of retroviral 
vectors to transduce in uiuo hepatocellular tumor cells 
cannot be formally excluded without attempting their 
infection. 
The initially most promising liver-directed gene 
therapy strategies address diseases in which genetic 
supplementation of a small percent of cells could lead to 
a therapeutic effect. If only a small fraction of hepato- 
cytes in a patient with HCC were transduced using this 
strategy, it would be unlikely to achieve a clinical effect. 
Initial gene therapy protocols addressing the treatment 
of malignancies have attempted to target tumors with 
immune modifiers so that transduction of a small 
percentage of the tumor cells could potentially have a 
clinical impact (4). 
In summary, a thorough and provocative series of in 
uitro experiments were presented in this article. It is 
anticipated that more than a small fraction of tumor 
cells would have to be targeted with the gene therapy 
vector to ablate HCC in uiuo using this strategy. 
Substantive advances in in uiuo liver-directed gene 
transfer efficiency will be necessary for such an approach 
to cure HCC. Given the clinical course of unresedable 
HCC, it is compelling to develop treatments that could 
prolong life expectancy and improve the quality of life. 
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